Literature DB >> 9533067

A primer on continuous renal replacement therapy for critically ill patients.

M S Joy1, G R Matzke, D K Armstrong, M A Marx, B J Zarowitz.   

Abstract

OBJECTIVES: To characterize the multiple continuous renal replacement therapy (CRRT) techniques available for the management of critically ill adults, and to review the indications for and complications of use, principles of drug removal during CRRT, drug dosage individualization guidelines, and the influence of CRRT on patient outcomes. DATA SOURCES: MEDLINE (January 1981-December 1996) was searched for appropriate publications by using terms such as hemofiltration, ultrafiltration, hemodialysis, hemodiafiltration, medications, and pharmacokinetics; selected articles were cross-referenced. STUDY SELECTION: References selected were those considered to enhance the reader's knowledge of the principles of CRRT, and to provide adequate therapies on drug disposition. DATA SYNTHESIS: CRRTs use filtration/convection and in some cases diffusion to treat hemodynamically unstable patients with fluid overload and/or acute renal failure. Recent data suggest that positive outcomes may also be attained in patients with other medical conditions such as septic shock, multiple organ dysfunction syndrome, and hepatic failure. Age, ventilator support, inotropic support, reduced urine volume, and elevated serum bilirubin concentrations have been associated with poor outcomes. Complications associated with CRRT include bleeding due to excessive anticoagulation and line disconnections, fluid and electrolyte imbalance, and filter and venous clotting. CRRT can complicate the medication regimens of patients for whom it is important to maintain drug plasma concentrations within a narrow therapeutic range. Since the physicochemical characteristics of a drug and procedure-specific factors can alter drug removal, a thorough assessment of all factors needs to be considered before dosage regimens are revised. In addition, an algorithm for drug dosing considerations based on drug and CRRT characteristics, as well as standard pharmacokinetic equations, is proposed.
CONCLUSIONS: The use of CRRT has expanded to encompass the treatment of disease states other than just acute renal failure. Since there is great variability among treatment centers, it is premature to conclude that there is enhanced survival in CRRT-treated patients compared with those who received conventional hemodialysis. This primer may help clinicians understand the need to individualize these therapies and to prospectively optimize the pharmacotherapy of their patients receiving CRRT.

Entities:  

Mesh:

Year:  1998        PMID: 9533067     DOI: 10.1345/aph.17105

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  19 in total

1.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Pharmacokinetic studies in patients on continuous renal replacement therapies.

Authors:  U F Kroh
Journal:  Intensive Care Med       Date:  2001-04       Impact factor: 17.440

3.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

4.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 5.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 7.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

9.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.